20 months after cannabis-based products for medicinal use were legalized in the UK, attitudes towards using them are still highly skeptical, say researchers.
Attitudes towards cannabis products for medicinal use need to change with much greater appropriate use of such products to help alleviate patients’ pain, suggests research published in the journal BMJ Open.
Researchers found that hundreds of thousands of UK patients were self-medicating with illegal cannabis-based products for medicinal use due to the fact that much of the medical and pharmacy professions have so far not embraced and prescribed legal cannabis-based products for their patients.
In November 2018 when the UK made cannabis-based products for medicinal use (CBPMs) legal, most people assumed these would immediately be made available to patients, but this has not happened.
In the year since then, almost no NHS prescriptions have been issued and less than a hundred have been made available from private providers at a cost of at least £1,000 a month.
Consequently, some parents of children with severe epilepsy continue to go overseas to get their children access to the only treatment which has proven to be effective for their condition — cannabinoid medication.
In addition, it is estimated that the vast majority of the estimated 1.4 million medical cannabis users source from the black market with its problems of illegality, unknown quality, content, and provenance.
This is despite the fact that there is existing substantial evidence of effectiveness with cannabis products for medicinal use in many disorders as identified in the US National Academy of Sciences review in 2017.
Researchers from Imperial College London, London School of Economics and Drug Science (formerly known as the Independent Scientific Committee on Drugs), therefore, set out to understand why the UK was lagging behind so many other countries that also have legalized medical cannabis.
They consulted with parents and patients, prescribers, pharmacists, and decision-makers.
They found that there appeared to be a series of distinct barriers to prescribing that needed to be overcome in order to improve patient access to medical cannabis in the UK.
These include concerns about a perceived lack of scientific evidence but the researchers said these concerns were misplaced because many patient-centered approaches including patient-reported outcomes, pharmacoepidemiology (study of the uses and effects of drugs) and trials involving a single patient could be applied.
International database evidence suggested this new class of drug offered a significant advance in treatment for many in whom current medicines were either ineffective or poorly tolerated.
Various reasons to explain why there was resistance to use of these drugs were given, such as the fact the use of medicinal cannabis products was something being driven by patients and not doctors, which the latter group might resent.
In addition, the current government’s insistence that medical cannabis be considered as a “special’ product, meant challenges for prescribers.
For example, they faced additional organizational bureaucracy and the prescriber had to hold responsibility for any untold harm caused unlike any other product for which responsibility lay with the manufacturer.
Another reason for the resistance to prescribing these products was that for almost 50 years, the medical profession focused on the risks of cannabis with claims of harm, including male sterility, lung cancer, and schizophrenia. Though these have now been largely debunked and were generally the result of recreational rather than prescribed medical use, many practitioners may not know this.
The researchers say that the many thousands of UK patients self-medicating with non-regulated cannabis products for medicinal use and the international evidence suggested these new medical products offered an advance in treatment for many people.
They also offered the potential of cost savings to the NHS in terms of reduced hospital stays and less prescribing of other medicines particularly opioids for chronic pain, they argued.
They conclude: “The failure of the medical and pharmacy professions to embrace CBPMs despite their being made ‘legal’ over 18 months ago is a great worry to patients” and may, they say, have led to preventable deaths from conditions such as epilepsy.
“We hope that this paper will help policymakers and prescribers understand the challenges to prescribing and so help them develop approaches to overcome the current highly unsatisfactory situation.”
Reference: “So near yet so far: why won’t the UK prescribe medical cannabis?” by David Nutt, Steve Bazire, Lawrence D Phillips and Anne Katrin Schlag, 22 September 2020, BMJ Open.